English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Methods A prospective, non-inferiority, open-label multicenter trial including patients pretreated with two or three classes of ARV, viral load (VL) = 3 to 5.5 log10 HIV-1 RNA copies/ ml and possible ARV optimized background with at least two active compounds. Patients were randomized 1:1 between the groups (ENF + OB, OB) after 28 weeks of induction with ENF + OB for patients achieving VL<400 copies/ml at week 16, and VL<50 copies/ml at week 24. The primary end-point was proportion of patients with VL< 50 copies/ml at week 52.

INDEED study: final results of an induction treatment strategy with enfuvirtide in treatment failure patients